T2 FLAIR sequences. LQ less than 0.3 was considered RN. Result: Twenty-two patients were followed for a median 320 days. Sixteen patients developed radionecrosis in 21 of 62 lesions (33%), four of which were symptomatic (20%). Eleven of these lesions received 3 fractions and ten received one fraction. RN risk increased with increasing tumor volume (log odds ratio=1.12, p=0.04). There was no difference in incidence of RN in patients who received whole brain radiotherapy (WBRT) (p=0.11), hypo-fractionation (p=0.98) or had a higher maximum dose (p=0.71). Radiographic RN, however, did not clear in any patients who developed it. Eight patients developed a local recurrence (12%), six of which occurred in the single fraction group. Conclusion: Radionecrosis was significantly related to tumor volume but not fractionation, WBRT, or maximum dose. Overall, our results indicate patients receiving SRS for multiple brain metastasis have a higher rate of radionecrosis than the literature and poorer survival despite having equivalent local control.

doi:10.1017/cjn.2018.277

Extent of resection in glioblastoma: Incorporating clinical and molecular data

Julie Semenchuk, Dr. Marshall Pitz, Dr. Marco Essig, Pascal Lambert, Katie Galloway. semench3@myumanitoba.ca

Background: The benefits of increasing extent of resection (EOR) for both overall survival and progression-free survival (PFS) in glioblastoma has been well documented. However, models predicting surgical outcomes have failed to incorporate a patient’s IDH status, a known prognostic factor. We isolate the impact of IDH on surgical outcomes. We determine the effect modification of increasing EOR and decreasing residual tumor volume (RTV) on IDH status. Methods: We performed a retrospective cohort study of 98 patients with glioblastoma who had undergone either biopsy or surgical resection. Tumor volumes were determined by volumetric analysis. Univariable and multivariable Cox PH Regression models were built using overall survival and PFS as endpoints. Results: Increasing EOR and decreasing RTV were both associated with prolonged overall survival and PFS. When IDH status was added to multivariable models, the model utilizing RTV provided a slightly better fit compared to EOR. An interaction term between RTV and IDH status was characterized, such that at low RTVs the prognosis of an IDH mutant is significantly better than that of an IDH wild-type, an effect that is less important as RTV increases. The significance of this term was confirmed by improved fit upon insertion into multivariable models. Conclusion: Minimizing RTV and increasing EOR are important prognostic factors for both IDH wild-type and IDH mutant glioblastoma. The protective benefit of the IDH mutation at lower RTVs suggests these patients are the best candidates for aggressive surgical resection.

doi:10.1017/cjn.2018.279

Untangling the NFI-Calpain signaling axis in malignant glioma

Kevin Vo, Rebecca Burchett, Miranda Brun, and Roseline Godbout. kv1991@outlook.com

Malignant gliomas (MG) are highly infiltrative tumours with a poor prognosis. Nuclear factor I (NFI) is a family of 4 transcription factors (NFIA, B, C and X) implicated in the regulation of genes involved in MG cell migration and infiltration, particularly the neural stem cell marker, brain fatty acid binding protein (B-FABP). NFI activity is regulated by its phosphorylation status, with hypophosphorylated NFI being the active form. Our results indicate that the phosphatase calcineurin is able to dephosphorylate NFI. In turn, calcineurin is cleaved and activated by calpain proteases. We have identified CAST, a gene that encodes calpain inhibitor, calpastatin, as a putative target of NFI based on chromatin immunoprecipitation. Putative NFI binding elements are located in intron 3 of the CAST gene. To determine whether there is a bona fide alternative promoter within intron 3 of CAST, we carried out gel shifts as well as luciferase reporter gene assays using both the canonical and alternative promoters of CAST. These assays confirmed CAST alternative promoter usage in MG cells. Knockdown of individual NFIs revealed a role for NFIC and NFIX in the repression of CAST gene expression, specifically in cells expressing the hypophosphorylated (active) form of NFI. NFI depletion also altered the subcellular localization of both calpain and calcineurin protein. Our results suggest a feedback loop for the

doi:10.1017/cjn.2018.278

The impact of repeated surgery on survival for patients with recurrent glioblastoma

Nassiri F, Badhiwala J, Wang J, Zadeh G. farshad.nassiri@mail.utoronto.ca

Background: Recurrent glioblastoma portends a poor prognosis and the role of repeat surgery in improving survival remains uncertain. Therefore, we undertook a systematic review and meta-analysis in order to determine if repeat surgical resection provides a meaningful survival benefit for patients with recurrent glioblastoma. Methods: Two independent reviewers searched for articles that reported on overall-survival of patients with recurrent glioblastoma using MEDLINE, Embase, Google Scholar, and Cochrane from January 2000 to 2018. Studies that compared overall survival of patients treated with single surgery compared to repeat surgery in the temozolomide era were included for analysis. Primary outcomes were odds ratio for survival at 6, 12, and 24 months from date of initial diagnosis. Secondary outcomes were ratio odds ratio for survival at 6, 12, and 24 months from date of repeat surgery. The proportions of patients who had the outcomes of interest were pooled using random-effects model. Quality assessment was performed using the Newcastle Ottawa Scale. Heterogeneity across trials was quantified by the I2 statistic. Publication bias was evaluated visually using funnel plots and quantified by the Egger regression. Results: Fourteen articles reporting on 3048 patients were included for analysis. The majority of articles were deemed to be of high quality with Newcastle Ottawa scale greater than 7 points. Pooled analysis showed improved overall survival following repeat surgery at 6- (OR 1.73, 95% CI 1.23-2.45, p < 0.05), 12- (OR 1.71, 95% CI 1.20-2.45, p < 0.05), and 24-months (OR 2.24, 95% CI 1.01-4.95, p < 0.05) from from date of initial diagnosis and from date of initial diagnosis at 6- (OR 8.22, 95% CI 5.23-12.93, p < 0.01), 12- (OR 4.16, 95% CI 3.25-5.36, p < 0.01), and 24- (2.35, 95% CI 1.77-3.11, p < 0.05) months. Conclusions: Repeat surgery for recurrent glioblastoma is associated with a significant survival advantage independent of other salvage therapies that include chemotherapy, radiation, and other antineoplastic regimens.

doi:10.1017/cjn.2018.277

Suppl 3 – 57